Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 15, 2021 07:00 ET | Source: Emergex Vaccines Holding Ltd

Emergex announces approval to initiate Phase I clinical trial of its next generation COVID-19 vaccine candidate

PRESS RELEASE Emergex announces approval to initiate Phase I clinical trial of its next generation COVID-19 vaccine candidate Synthetic vaccine designed to prime T-Cells to rapidly remove...
November 15, 2021 02:00 ET | Source: Emergex Vaccines Holding Ltd

Emergex announces approval to initiate Phase I clinical trial of its next generation COVID-19 vaccine candidate

PRESS RELEASE Emergex announces approval to initiate Phase I clinical trial of its next generation COVID-19 vaccine candidate Synthetic vaccine designed to prime T-Cells to rapidly remove...
June 30, 2021 02:00 ET | Source: Emergex Vaccines Holding Ltd

Emergex Receives Regulatory Approval for a Phase I Clinical Trial in Dengue of a T-Cell Priming Vaccine

PRESS RELEASE Emergex Receives Regulatory Approval for a Phase I Clinical Trial in Dengue of a T-Cell Priming Vaccine Swiss regulatory authorities, including the Swiss Agency for Therapeutic...
September 15, 2020 07:00 ET | Source: Emergex Vaccines Holding Ltd

Emergex Vaccines and George Mason University Identify T-Cell Epitopes Presented by SARS-Cov-2 Infected Cells

PRESS RELEASE Emergex Vaccines and George Mason University Identify T-Cell Epitopes Presented by SARS-Cov-2 Infected Cells First detailed, empirical analysis of Class 1 epitopes presented by...
September 15, 2020 02:00 ET | Source: Emergex Vaccines Holding Ltd

Emergex Vaccines and George Mason University Identify T-Cell Epitopes Presented by SARS-Cov-2 Infected Cells

PRESS RELEASE Emergex Vaccines and George Mason University Identify T-Cell Epitopes Presented by SARS-Cov-2 Infected Cells First detailed, empirical analysis of Class 1 epitopes presented by...